$AEMD

AETHLON MEDICAL INC

CIK:0000882291|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
OPERATING EXPENSES
Professional fees	$ 333,569	$ 476,032
Payroll and related expenses	583,183	581,000
General and administrative	662,450	735,358
Total operating expenses	1,579,202	1,792,390
OPERATING LOSS	(1,579,202)	(1,792,390)
INTEREST INCOME, NET	31,290	30,532
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(1,547,912)	(1,761,858)
OTHER COMPREHENSIVE LOSS	(6,186)	(5,244)
COMPREHENSIVE LOSS	$ (1,554,098)	$ (1,767,102)
Basic net loss per share attributable to common stockholders	$ (4.02)	$ (42.42)
Diluted net loss per share attributable to common stockholders	$ (4.02)	$ (42.42)
Weighted average number of common shares outstanding - basic	384,705	41,529
Weighted average number of common shares outstanding - diluted	384,705	41,529

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows used in operating activities:
Net loss	$ (1,547,912)	$ (1,761,858)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	72,860	82,637
Stock based compensation	50,000	72,442
Amortization of right-of-use operating lease asset	75,625	72,270
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	79,879	164,031
Accounts payable and other current liabilities	(626,991)	(137,492)
Due to related parties	0	(206,967)
Net cash used in operating activities	(1,896,539)	(1,714,937)
Cash flows used in investing activities:
Purchases of property and equipment	(9,150)	0
Cash used in investing activities	(9,150)	0
Cash flows provided (used in) by financing activities:
Proceeds from the issuance of common stock	1,904,211	0
Payments for offering costs related to equity issuance exercises	(82,568)	0
Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense	(4,488)	(5,357)
Net cash provided (used in) by financing activities	1,817,155	(5,357)
Effect of exchange rate on changes on cash	(4,123)	(15,496)
Net decrease in cash, cash equivalents and restricted cash	(92,657)	(1,735,790)
Cash, cash equivalents and restricted cash at beginning of period	5,125,386	5,599,074
Cash, cash equivalents and restricted cash	5,032,729	3,863,284
Supplemental disclosures of non-cash investing and financing activities:
Par value of shares issued for vested restricted stock units and net stock option exercise	0.03	0.0027
Deferred offering costs not yet paid	214,015	0
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents	4,933,579	3,765,154
Restricted cash	$ 99,150	$ 98,130

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Mar. 31, 2026
Current assets
Cash and cash equivalents	$ 4,933,579	$ 5,026,458
Deferred offering cost	394,192	210,985
Prepaid expenses and other current assets	283,143	332,094
Total current assets	5,610,914	5,569,537
Property and equipment, net	293,112	356,822
Operating lease right-of-use asset, net	232,195	307,820
Restricted cash	99,150	98,928
Total assets	6,235,371	6,333,107
Current liabilities
Accounts payable	411,373	384,550
Due to related parties	68,250	68,250
Operating lease liability, current portion	255,052	336,718
Other current liabilities	301,367	657,317
Total liabilities, all current	1,036,042	1,446,835
Stockholders’ Equity
Common stock, par value $0.001 per share; 20,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 477,402 shares issued and outstanding as of June 30, 2026 and 314,100 shares issued and outstanding at March 31, 2026.	477	314
Additional paid-in capital	181,891,939	180,024,947
Accumulated other comprehensive loss	(38,889)	(32,703)
Accumulated deficit	(176,654,198)	(175,106,286)
Total stockholders’ equity	5,199,329	4,886,272
Total liabilities and stockholders’ equity	$ 6,235,371	$ 6,333,107